Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo aims to outsmart resistant lung cancer

NCT ID NCT07315113

Disease control Sponsor: Nuvectis Pharma, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This early-phase trial tests a new oral drug called NXP900 combined with the standard drug osimertinib in 18 adults with advanced EGFR-mutated non-small cell lung cancer that has progressed on prior osimertinib. The main goals are to check safety and see if the combination can shrink tumors or control the disease. Because it is a Phase 1 study, the focus is on finding the right dose and watching for side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
NXP900 combined with osimertinib
What this could lead to
If it works, this could point toward a new combination treatment for advanced EGFR-mutated lung cancer that has stopped responding to osimertinib alone.
What could go wrong
This is a very early Phase 1b trial with only 18 participants, so it is primarily testing safety and dosing. The combination may not shrink tumors or may cause unexpected side effects.
Why investors are watching

Nuvectis Pharma is testing its experimental drug NXP900 together with the standard lung cancer medicine osimertinib in 18 patients whose EGFR-mutated non-small cell lung cancer has stopped responding to treatment. For a micro-cap company with few assets, this early-stage readout on safety and disease control is a major value driver, because a favorable result could validate the combination and support further development.

If it works: A positive result could show that NXP900 adds benefit in patients who have progressed on osimertinib, which would strengthen Nuvectis's case for advancing the drug into later trials and could attract partnership interest.

If it fails: The trial could fail to show adequate safety or disease control, or the small sample size could produce unclear results. Early-stage cancer trials often fail, and a negative outcome would leave Nuvectis with limited options and could delay or end the program.

AI-written from the trial record. Speculative, and not investment advice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 18 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provide written informed consent. 2. 18 years old or older. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC. 5. Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting. Exclusion Criteria: 1. Subject's cancer has a known oncogenic driver alteration other than EGFR. 2. Known EGFR mutations that cause resistance to osimertinib 3. Known human epidermal growth factor receptor 2 (HER2) overexpression 4. Any contraindications to treatment with osimertinib

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EGFR mutated non-small cell lung cancer patients are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EGFR mutated non-small cell lung cancer patients EGFR mutation positive non-small cell lung cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    6 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Maryland Oncology Hematology

    RECRUITING

    Calverton, Maryland, 20705, United States

  • Massachusetts General Hospital

    NOT_YET_RECRUITING

    Boston, Massachusetts, 02114, United States

  • NEXT Houston

    RECRUITING

    Houston, Texas, 77054, United States

  • NEXT Virginia

    RECRUITING

    Fairfax, Virginia, 22031, United States

  • UPMC Hillman Cancer Center

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • Willamette Valley Cancer Institute and Research Center

    RECRUITING

    Eugene, Oregon, 97401, United States